IMU-856

August 24, 2020August 24, 2020

1st Healthy Volunteer Dosed in Phase 1 Trial of Potential IBD Treatment IMU-856

News

The first healthy volunteer has been dosed in an Australian Phase 1 clinical trial investigating IMU-856, a potential novel treatment for inflammatory bowel disease (IBD), according to the therapy’s developer Immunic ... Read more

January 17, 2020January 17, 2020

IMU-856 Restores Gut Barrier Function, Key for Halting IBD Progression, Preclinical Data Suggests

News

The oral small molecule IMU-856, now being developed by Immunic Therapeutics, strengthens and improves the barrier function of intestinal cells while having little to no effect on the immune system, preclinical ... Read more

January 2, 2019January 2, 2019

Immunic Will Develop IMU-856, Promising IBD Therapy

News

Immunic earned the exclusive rights to develop a group of innovative disease-modifying therapies, now renamed IMU-856, for inflammatory bowel disease (IBD). IMU-856, originally developed by Daiichi Sankyo, is an oral small ... Read more